Tags

Type your tag names separated by a space and hit enter

CoVaccine HT™ Adjuvant Potentiates Robust Immune Responses to Recombinant SARS-CoV-2 Spike S1 Immunization.
Front Immunol. 2020; 11:599587.FI

Abstract

The current COVID-19 pandemic has claimed hundreds of thousands of lives and its causative agent, SARS-CoV-2, has infected millions, globally. The highly contagious nature of this respiratory virus has spurred massive global efforts to develop vaccines at record speeds. In addition to enhanced immunogen delivery, adjuvants may greatly impact protective efficacy of a SARS-CoV-2 vaccine. To investigate adjuvant suitability, we formulated protein subunit vaccines consisting of the recombinant S1 domain of SARS-CoV-2 Spike protein alone or in combination with either CoVaccine HT™ or Alhydrogel. CoVaccine HT™ induced high titres of antigen-binding IgG after a single dose, facilitated affinity maturation and class switching to a greater extent than Alhydrogel and elicited potent cell-mediated immunity as well as virus neutralizing antibody titres. Data presented here suggests that adjuvantation with CoVaccine HT™ can rapidly induce a comprehensive and protective immune response to SARS-CoV-2.

Authors+Show Affiliations

Department of Tropical Medicine, John A. Burns School of Medicine, University of Hawaii, Honolulu, HI, United States. Cell and Molecular Biology Graduate Program, John A. Burns School of Medicine, University of Hawaii, Honolulu, HI, United States.Department of Tropical Medicine, John A. Burns School of Medicine, University of Hawaii, Honolulu, HI, United States.Department of Tropical Medicine, John A. Burns School of Medicine, University of Hawaii, Honolulu, HI, United States.Department of Tropical Medicine, John A. Burns School of Medicine, University of Hawaii, Honolulu, HI, United States.Department of Tropical Medicine, John A. Burns School of Medicine, University of Hawaii, Honolulu, HI, United States.BIOQUAL, Inc., Rockville, MD, United States.BIOQUAL, Inc., Rockville, MD, United States.Department of Tropical Medicine, John A. Burns School of Medicine, University of Hawaii, Honolulu, HI, United States. Cell and Molecular Biology Graduate Program, John A. Burns School of Medicine, University of Hawaii, Honolulu, HI, United States.

Pub Type(s)

Journal Article
Research Support, N.I.H., Extramural

Language

eng

PubMed ID

33193454

Citation

Haun, Brien K., et al. "CoVaccine HT™ Adjuvant Potentiates Robust Immune Responses to Recombinant SARS-CoV-2 Spike S1 Immunization." Frontiers in Immunology, vol. 11, 2020, p. 599587.
Haun BK, Lai CY, Williams CA, et al. CoVaccine HT™ Adjuvant Potentiates Robust Immune Responses to Recombinant SARS-CoV-2 Spike S1 Immunization. Front Immunol. 2020;11:599587.
Haun, B. K., Lai, C. Y., Williams, C. A., Wong, T. A. S., Lieberman, M. M., Pessaint, L., Andersen, H., & Lehrer, A. T. (2020). CoVaccine HT™ Adjuvant Potentiates Robust Immune Responses to Recombinant SARS-CoV-2 Spike S1 Immunization. Frontiers in Immunology, 11, 599587. https://doi.org/10.3389/fimmu.2020.599587
Haun BK, et al. CoVaccine HT™ Adjuvant Potentiates Robust Immune Responses to Recombinant SARS-CoV-2 Spike S1 Immunization. Front Immunol. 2020;11:599587. PubMed PMID: 33193454.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - CoVaccine HT™ Adjuvant Potentiates Robust Immune Responses to Recombinant SARS-CoV-2 Spike S1 Immunization. AU - Haun,Brien K, AU - Lai,Chih-Yun, AU - Williams,Caitlin A, AU - Wong,Teri Ann S, AU - Lieberman,Michael M, AU - Pessaint,Laurent, AU - Andersen,Hanne, AU - Lehrer,Axel T, Y1 - 2020/10/30/ PY - 2020/08/27/received PY - 2020/10/06/accepted PY - 2020/11/16/entrez PY - 2020/11/17/pubmed PY - 2020/11/17/medline KW - COVID-19 KW - SARS-CoV-2 KW - adjuvant KW - immunogenicity KW - rapid response KW - recombinant subunit SP - 599587 EP - 599587 JF - Frontiers in immunology JO - Front Immunol VL - 11 N2 - The current COVID-19 pandemic has claimed hundreds of thousands of lives and its causative agent, SARS-CoV-2, has infected millions, globally. The highly contagious nature of this respiratory virus has spurred massive global efforts to develop vaccines at record speeds. In addition to enhanced immunogen delivery, adjuvants may greatly impact protective efficacy of a SARS-CoV-2 vaccine. To investigate adjuvant suitability, we formulated protein subunit vaccines consisting of the recombinant S1 domain of SARS-CoV-2 Spike protein alone or in combination with either CoVaccine HT™ or Alhydrogel. CoVaccine HT™ induced high titres of antigen-binding IgG after a single dose, facilitated affinity maturation and class switching to a greater extent than Alhydrogel and elicited potent cell-mediated immunity as well as virus neutralizing antibody titres. Data presented here suggests that adjuvantation with CoVaccine HT™ can rapidly induce a comprehensive and protective immune response to SARS-CoV-2. SN - 1664-3224 UR - https://www.unboundmedicine.com/medline/citation/33193454/CoVaccine_HT™_Adjuvant_Potentiates_Robust_Immune_Responses_to_Recombinant_SARS_CoV_2_Spike_S1_Immunization_ L2 - https://doi.org/10.3389/fimmu.2020.599587 DB - PRIME DP - Unbound Medicine ER -